US FDA approved new drug Mavyret that contains combination of drugs for the treatment of chronic hepatitis C without cirrhosis or with mild cirhosis. Mavyret contains 2 kind of drugs that include glecaprevir in 100mg strength and pibrentasvir in 40mg strength. Mavyret is indicated for the treatment of chronic hepatitis c having genotype 1 to 6.
Hepatitis C is characterized as chronic infection caused by virus that belongs to virus family Flaviviridae. Virus of Hepatitis C is single stranded RNA virus having 7 different kinds of genotypes 1 to 7. Genotypes that have high prevalence rate are 1,2,3 and 4. At beginning of disease patient have minute or low intensity symptoms like dark urine, yellowish tinged color skin, mild pain in abdomen and mild fever,
Transmission of hepatitis C virus mainly occurs via blood to blood contact in the form of contaminated nail cutters, tooth brush, syringes, razors, needles, piercing equipment etc. Contaminated blood transfusion is another leading cause that spreads hepatitis C. Cases of vertical transmission (spread through an infected mother to her baby during birth) of hepatitis c are consistently increasing in USA.
Unfortunately, during early stages virus silently kills hepatocytes and patient remains unaware of such damage but after 60% to 70% damage of liver symptoms become sever and intense. So far, there is no vaccine for hepatitis c due to diversity in genotype of hepatitis c virus. In later stages, patient usually feels symptoms like fever, blood in vomit or tool, loss of appetite, fatigue, nausea, muscle and weakness. At cirrhosis stage liver becomes inflamed and it causes internal hemorrhaging, portal hypertension and ascites.
Mavyret shows promising results during clinical trials but treatment duration with Mavyret depends upon number of factor like treatment history, viral genotype, and cirrhosis status.
Mavyret Side effects
According to health authorities following side effects were observed during clinical trials of Mavyret.
- Muscle weakness
- Abdominal discomfort
- Mild Fever
US FDA approved Mavyret for the treatment of chronic hepatitis C without cirrhosis or with mild cirhosis. Mavyret is indicated for the treatment of chronic hepatitis having genotype 1 to 6. In case of advance cirrhosis of severe cirrhosis this drug should be avoided.
Mavyret contains 2 kind of drugs that include glecaprevir in 100mg strength and pibrentasvir in 40mg strength. In adults, standard dosing frequency of Mavyret is 3 tablets per day with food for 8 weeks. Dose titration must be considered in case of liver or hepatic impairment.